Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Science Officer | February 27, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date February 27, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 152,408 |
Reported balance
After 2019-02-27 transaction · row 1
1 source rowRow 1 · 2019-02-27 · Exercise / conversion · Acquired 6,945 · Balance 152,408 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,888 |
Reported balance
After 2019-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-27 · Exercise / conversion · Disposed 6,945 · Balance 13,888 F1: Fully vested as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Mar 1, 2019 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 6,945 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015000 · doc4.xml · derivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,888 Underlying: Ordinary Shares · 6,945 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:34 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,945 | $52.90 | $367,390.50 |
DisclosureSEC source: 0001209191-19-015000 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:57 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 36,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013680 · doc4.xml · derivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,399 Underlying: Ordinary Shares · 36,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:57 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 36,400 | $53.38 | $1,943,032.00 |
DisclosureSEC source: 0001209191-19-013680 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 68,813 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-004549 · doc4.xml · derivative · entry 6 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,522 Underlying: Ordinary Shares · 68,813 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 68,813 | $45.25 | $3,113,788.25 |
DisclosureSEC source: 0001209191-19-004549 · doc4.xml · nonDerivative · entry 4 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,063 F3 · price: On January 17, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 68,813 shares in multiple trades at prices ranging from $45.00 to $45.66. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 68,813 | $14.37 | $988,842.81 |
DisclosureSEC source: 0001209191-19-004549 · doc4.xml · nonDerivative · entry 3 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 100,000 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-19-004549 · doc4.xml · derivative · entry 5 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,335 Underlying: Ordinary Shares · 100,000 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and currently exercisable as of the date hereof. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100,000 | $45.11 | $4,511,000.00 |
DisclosureSEC source: 0001209191-19-004549 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,063 F2 · price: On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 100,000 shares in multiple trades at prices ranging from $45.00 to $45.36. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 100,000 | $14.37 | $1,437,000.00 |
DisclosureSEC source: 0001209191-19-004549 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,231 | $17.26 | $21,240.91 |
DisclosureSEC source: 0001209191-18-042137 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,063 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2018 through June 30, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 2, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 37,500 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001209191-18-038050 · doc4.xml · derivative · entry 4 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 37,500 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,750 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001209191-18-038050 · doc4.xml · derivative · entry 3 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,335 Underlying: Ordinary Shares · 30,750 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 37,500 | $11.46 | $429,750.00 |
DisclosureSEC source: 0001209191-18-038050 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,750 | $14.37 | $441,877.50 |
DisclosureSEC source: 0001209191-18-038050 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 68,250 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · derivative · entry 10 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,750 Underlying: Ordinary Shares · 68,250 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 59,130 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · derivative · entry 9 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 59,130 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 218,781 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · derivative · entry 8 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 218,781 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,131 | $31.74 | $131,117.94 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 7 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,582 F4 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 4,131 shares in multiple trades at prices ranging from $31.00 to $31.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,800 | $30.26 | $54,468.00 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 6 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,713 F3 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 1,800 shares in multiple trades at prices ranging from $30.00 to $30.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 114,934 | $29.36 | $3,374,462.24 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 5 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,513 F2 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 114,934 shares in multiple trades at prices ranging from $29.00 to $29.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 68,250 | $7.15 | $487,987.50 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 4 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 59,130 | $7.48 | $442,292.40 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 3 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 225,296 | $28.60 | $6,443,465.60 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,067 F1 · price: On June 4, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 225,296 shares in multiple trades at prices ranging from $28.00 to $28.99. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 17:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 218,781 | $7.03 | $1,538,030.43 |
DisclosureSEC source: 0001209191-18-036127 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 70,956 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-025732 · doc4.xml · derivative · entry 6 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 70,956 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 76,869 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-18-025732 · doc4.xml · derivative · entry 5 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 76,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 70,956 | $24.00 | $1,702,944.00 |
DisclosureSEC source: 0001209191-18-025732 · doc4.xml · nonDerivative · entry 4 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,582 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 70,956 | $3.44 | $244,088.64 |
DisclosureSEC source: 0001209191-18-025732 · doc4.xml · nonDerivative · entry 3 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 76,869 | $24.00 | $1,844,856.00 |
DisclosureSEC source: 0001209191-18-025732 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,582 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 16:53 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 76,869 | $3.44 | $264,429.36 |
DisclosureSEC source: 0001209191-18-025732 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 20,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015010 · doc4.xml · derivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,833 Underlying: Ordinary Shares · 20,833 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 152,068 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-18-015010 · doc4.xml · derivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,068 Underlying: Ordinary Shares · 152,068 shares Expires 2028-02-27 F1 · derivative.exercise_date: Options to buy 152,068 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 17:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 36,401 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013425 · doc4.xml · derivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,799 Underlying: Ordinary Shares · 36,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 17:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 36,401 | $21.55 | $784,441.55 |
DisclosureSEC source: 0001209191-18-013425 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:01 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 25,320 | $22.00 | $557,126.09 |
DisclosureSEC source: 0001209191-18-003629 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,181 F1 · price: On January 11, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 25,320 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,100 | $22.00 | $200,200.00 |
DisclosureSEC source: 0001209191-17-059742 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,501 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| November 03, 2017 Filed Nov 6, 2017 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,100 | $22.00 | $68,200.00 |
DisclosureSEC source: 0001209191-17-059404 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,601 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 16:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $22.00 | $6,600.00 |
DisclosureSEC source: 0001209191-17-059404 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,701 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,119 | $22.01 | $486,810.44 |
DisclosureSEC source: 0001209191-17-058849 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,001 F2 · price: On November 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 22,119 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 150 | $22.00 | $3,300.00 |
DisclosureSEC source: 0001209191-17-058849 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,120 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 16:19 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 1,900 | $22.03 | $41,864.98 |
DisclosureSEC source: 0001209191-17-054126 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,270 F1 · price: On September 25, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 1,900 shares in multiple trades at prices ranging from $22.00 to $22.05. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 2,500 | $22.03 | $55,080.00 |
DisclosureSEC source: 0001209191-17-052952 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,170 F2 · price: On September 14, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 2,500 shares in multiple trades at prices ranging from $22.00 to $22.25. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 46,872 | $22.01 | $1,031,765.21 |
DisclosureSEC source: 0001209191-17-052952 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,670 F1 · price: On September 13, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 46,872 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 111,361 | $18.14 | $2,020,533.98 |
DisclosureSEC source: 0001209191-17-044395 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,542 F3 · price: On July 5, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 111,361 shares in multiple trades at prices ranging from $18.00 to $18.35. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 3,181 | $6.67 | $21,226.81 |
DisclosureSEC source: 0001209191-17-044395 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,903 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017. Read SEC document |
| June 21, 2017 Filed Jun 22, 2017 16:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 66,361 | $16.78 | $1,113,205.78 |
DisclosureSEC source: 0001209191-17-041382 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,722 F1 · price: On June 21, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 66,361 shares in multiple trades at prices ranging from $16.60 to $17.50. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 16:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,000 | $15.06 | $225,885.00 |
DisclosureSEC source: 0001209191-17-041202 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,083 F1 · price: On June 19, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 15,000 shares in multiple trades at prices ranging from $15.00 to $15.20. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,044 | $15.01 | $135,768.53 |
DisclosureSEC source: 0001209191-17-040155 · doc4.xml · nonDerivative · entry 1 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,083 F1 · price: On June 13, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 9,044 shares in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 18:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,956 | $15.08 | $89,828.39 |
DisclosureSEC source: 0001209191-17-039655 · doc4.xml · nonDerivative · entry 2 Kirson Eilon D. · CIK 0001654356 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,127 F2 · price: On June 12, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 5,956 shares in multiple trades at prices ranging from $15.00 to $15.225. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.